Brainomix is highlighting success from its partnership with Argenica Therapeutics on a phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke.
Analysis using the Brainomix 360 Stroke AI imaging platform, cleared by the U.S. Food and Drug Administration (FDA) and CE-marked, showed statistically significant and clinically meaningful efficacy of ARG-007 in severe acute ischemic stroke patients. The platform helped quantify digital imaging biomarkers. And the company's e-ASPECTS, a decision support tool for assessing stroke signs on plain CT brain scans, allowed for improved stratification of patients.
The study assessed variability in baseline stroke severity assessment by applying standardized, objective AI imaging biomarkers to the trial data. Brainomix said its Brainomix 360 Stroke showed that patients with larger infarcts at presentation experienced statistically significant improvements in neurological function at 24 hours and disability outcomes at 90 days when treated with ARG-007 compared with placebo.
Brainomix also said the study showed that these patients demonstrated significantly smaller final infarct volumes.
